Status:
COMPLETED
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Eligibility:
FEMALE
20-45 years
Phase:
PHASE1
Brief Summary
This study is being conducted to evaluate the safety and tolerability of ascending multiple oral doses of SCA-136 adminstered to healthy Japanese and non-Japanese female subjects.
Eligibility Criteria
Inclusion
- Healthy Japanese women or non-Japanese of child bearing potential using nonhormonal contraceptives.
- Japanese female subjects are defined as being born in Japan but living outside of Japan for less than 5 years.
Exclusion
- Any significant disease.
- Positive urine drug screen, increased liver funtion tests, use of prescription drugs.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00458107
Start Date
April 1 2007
End Date
September 1 2007
Last Update
December 5 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glendale, California, United States, 91206